InvestmentAug 3, 2026, 04:38 PM
NewcelX Raises $1.4M in Private Placement; Warrants Could Add $1.5M
AI Summary
NewcelX Ltd. announced a private placement financing with certain accredited investors, expecting to raise $1.4 million in gross proceeds. The offering includes the sale of 347,134 common shares or pre-funded warrants at $4.033 per share, along with common warrants that could generate an additional $1.5 million upon full exercise. The company intends to use the net proceeds to advance its lead program, NCEL-101 for Type 1 Diabetes, in collaboration with Eledon Pharmaceuticals, and for general corporate purposes. The closing is anticipated around August 14, 2026.
Key Highlights
- NewcelX entered into definitive agreements for a private placement financing with accredited investors.
- Investors agreed to purchase 347,134 common shares or pre-funded warrants at $4.033 per share.
- Common warrants were issued to purchase up to 347,134 common shares at an exercise price of $4.437 per share.
- The offering is expected to generate gross proceeds of $1.4 million for the company.
- Full cash exercise of the warrants could result in an additional $1.5 million in gross proceeds.
- Net proceeds will primarily advance NCEL-101, NewcelX’s lead program for Type 1 Diabetes, with Eledon Pharmaceuticals.
- Funds will also be used for working capital and general corporate purposes.
- The offering is expected to close on or about August 14, 2026, subject to customary conditions.
Price Impact
More from NCEL